# Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)

> **NCT04523883** · PHASE2 · UNKNOWN · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 316 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **RADIATION:** postoperative radiotherapy
- **DRUG:** JS001

## Key facts

- **NCT ID:** NCT04523883
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-10
- **Primary completion:** 2022-08-09
- **Final completion:** 2024-08-09
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2021-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523883, "Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04523883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*